INTRODUCTION

Schizophrenia affects ~1% of the adult population. The disease is characterized by a broad range of positive, negative and cognitive symptoms. The exact pathogenesis of schizophrenia is unknown; however, several signs indicate the role of a disturbed glutamatergic system in the prodromal phase of schizophrenia, including cognitive deficits that can be reversed by treatment with N-acetylcysteine, which was also found to be effective in human patients. Here, we show that G72 transgenic mice have larger excitatory synapses with an increased amount of N-methyl-d-aspartate (NMDA) receptors in the molecular layer of DG, compared with wild-type littermates. Furthermore, transgenic animals have lower number of dentate granule cells with a parallel, but an even stronger decrease in the number of excitatory synapses in the molecular layer. Importantly, we also show that treatment with N-acetylcysteine can effectively normalize all these changes in transgenic animals, resulting in a state similar to wild-type mice. Our results show that G72 transcripts induce robust alterations in the glutamatergic system at the synaptic level that can be rescued with N-acetylcysteine treatment.

To examine physiological effects of the encoded proteins of G72, a ‘humanized’ transgenic mouse line was generated, carrying the entire human G72/G30 genomic region. These transgenic mice (G72Tg) encode splice variants similar to those present in the human brain. G72Tg mice showed behavioral alterations that are expected in a model of schizophrenia.22 They had an impaired spatial learning ability, suggesting damaged hippocampal function.23 and G72 mRNA expression was among the highest in the dentate gyrus (DG).22 Moreover, electrophysiological data revealed alterations at excitatory perforant path synapses in the DG, where G72 is expressed both in pre- and postsynaptic cells.23 Deformations of DG are reported to be predictive for schizophrenia.24 Inadequate maturation of dentate granule cells has been linked to neuropsychiatric disorders,25 and further morphological, functional and molecular dysfunctions of DG were observed in patients suffering from schizophrenia26,27 and bipolar disorder.28 These disorders share clinical features and genetic vulnerability,29 and G72 polymorphisms also correlate with the onset of bipolar disorder.30 Growing evidence indicates the role of oxidative stress in the generation of schizophrenia and bipolar disorder.31 In addition, mitochondrial dysfunctions, especially at complex I, are repeatedly observed in these disorders (see Discussion for details). LG72 has been shown to be located in mitochondria, influencing oxidative stress regulation20 and affecting mitochondrial morphology and dendritic arborization.21
reactive oxygen species. Glutathione (GSH) is the main antioxidant of the brain. Compared with healthy control subjects, patients suffering from schizophrenia or bipolar disorder have significantly lower GSH levels. Interestingly, treatment with N-acetylcysteine (NAC), a putative GSH precursor was shown to have beneficial effects on negative symptoms of reported schizophrenic cases, and on depressive symptoms in bipolar disorder. Similarly, G27Tg mice have decreased mitochondrial complex I activity and lower GSH levels, and NAC treatment rescued the above-mentioned spatial learning deficit in these G27Tg mice. In the present study, we reveal cellular and synaptic changes that may explain the spatial learning deficits and electrophysiological alterations of DG in the G27Tg animals. We demonstrate an increase in the size and NMDAR content of excitatory synapses on dentate granule-cell spines, which is accompanied by a decrease in the total number of excitatory synapses and granule cells in the DG. Most importantly, oral treatment with NAC almost completely restored these cellular and synaptic changes in G27Tg animals. These results can provide an explanation for the effectiveness of NAC treatment in human cases and can facilitate further research to alleviate negative symptoms in patients suffering from schizophrenia and bipolar disorder.

MATERIALS AND METHODS

Animals and tissue preparation

All experiments were performed in accordance with the institutional, governmental and European Union guidelines. G72 transgenic mice (G72Tg) were generated as described before. The ages of experimental animals were the following: litter number 1 (L11); 150 days (d), L2: 39 d, L3: 256 d, L4: 203 d, L5: 43 d, L6: 77 d, L7: 78 d, L8: 63 d, L9: 77 d. After weaning age (21 d), NAC-treated mice received 1 mg ml −1 NAC (A7250, Sigma-Aldrich, St. Louis, MO, USA) dissolved in tap water as their only drinking source for 6–8 weeks, whereas control mice drank tap water. Drinking water was refreshed twice a week, and mice drank on average 10 ml liquid per day (no difference was observed between groups). Overall, 22 male CD1 mice—9 wild type and 13 transgenic, of which 4 were treated with NAC—were anesthetized with inhalation of isoflurane, followed by intraperitoneal injection of an anesthetic mixture (containing 8.3 mg ml −1 ketamine, 1.7 mg ml −1 xylazine-hydrochloride, 0.8 mg ml −1 promethazine-nitric-oxide). Animals were perfused transcardially with 0.1 M phosphate buffer (PB, pH 7.4), followed by fixative for 40 min and finally PB for 10 min. Fixation contained 4% paraformaldehyde or 2% glutaraldehyde and 2% paraformaldehyde in PB (for synapse morphology and synapse stereology experiments). Coronal hippocampal sections were cut on Vibratome (VT12005, Leica Biosystems, Nussloch, Germany). Fifty-micrometer-thick sections were washed in PB, cryoprotected in 30% sucrose solution, put in vials, frozen in liquid nitrogen and stored at − 80 °C until further use. Two hundred fifty-micrometer-thick sections were processed immediately for freeze-substitution and low-temperature Lowicryl embedding directly after perfusions.

Synapse morphology measurements

A series of 50-μm-thick sections—250 μm apart from each other—were collected from the entire rostrocaudal extent of the hippocampi (from Bregma − 0.95 mm to − 4.03 mm) of 19 animals. After washing in PB, sections were treated with 0.5% osmium-tetroxide for 20 min, were dehydrated and embedded in Durcupan. During dehydration, sections were treated with 1% uranyl acetate. After polymerization, we prepared 70-nm-thick sections (Leica EM UC6) from the outer two-thirds of the molecular layer of DG, picked them up on formvar-coated single-slot copper grids and examined them using a Hitachi H-7100 (Hitachi, Tokyo, Japan) electron microscope (EM) and a Soft Imaging System Veleta CCD camera (EMISIS, Münster, Germany). Synaptic area was measured from serial sections of three-dimensional (3D) reconstructed synapses. We only included synapses that were cut near perpendicularly to the sectioning plane. After checking that the series of sections contained the whole synapse, the synaptic area was calculated by measuring the length of the synaptic active zone on each individual section of the same synapse, and then the sum was multiplied by the thickness of the sections (70 nm). The extent of the synaptic active zone was determined based on the extent of the postsynaptic density (PSD). For measurements, we used ImageJ (Fiji). For synaptic cleft width and PSD thickness measurements, synaptic and postsynaptic grayscale values were investigated. The distance between the two highest local grayscale maxima represented the actual synaptic cleft width, and the distance between the highest postsynaptic local maximum and the first local minimum represented the PSD thickness.

Post-embedding immunoelectron microscopy

Two hundred fifty-micrometer-thick sections from 11 animals were cryoprotected in 10 and 30% sucrose solutions. After slam-freezing on liquid nitrogen-cooled copper blocks, low-temperature dehydration was started at − 90 °C with dried methanol containing 0.5% uranyl acetate for 24 h. Freeze substitution was performed at − 45 °C using ascending mixtures of methanol and Lowicryl HM20 resin, and finally pure Lowicryl. Then, resin was polymerized using ultraviolet light. Seventy-nanometer-thick sections were picked up on formvar-coated single-slot nickel grids, blocked for 1 h and incubated on drops of primary antibodies overnight. The blocking solution, which was also used for diluting the primary and secondary antibodies, contained 2% human serum albumin and 0.03% Triton X-100 in Tris buffered saline. After incubation in primary antibody (rabbit anti-GluN1, 1:30, gift of professor Masahiko Watanabe) for 18 h, sections were washed in Tris buffered saline and incubated for 5 h on drops of secondary antibody (10-nm gold particle-conjugated goat anti-rabbit; British Biocell International, Cardiff, UK) diluted in blocking solution (1:100), which contained polyethylene glycol (0.5 mg ml −1 ). After washing in ultrapure water, sections were contrasted with saturated aqueous uranyl acetate. The specificity of the primary antibody has been tested by the laboratory of origin. The omission of the primary antibody resulted in no labeling. Forty-nanometer-wide bands were chosen on the two sides of the postsynaptic membrane as an area representing postsynaptic membrane-associated gold particle labeling. Synaptic areas were measured and synaptic gold particles were counted on each 3D-reconstructed synapse.

Stereology

The total volume of the outer two-thirds of the DG molecular layer was determined using the Stereo Investigator system (MBF Bioscience, Williston, VT, USA) in nine animals. From this volume, small regions were chosen randomly and 70-nm-thick section series were examined in EM using the physical disector method. Asymmetric synapses were collected within the counting frame (4 × 4–5 × 5 μm). From the physical disector volume and number of synapses, we calculated synapse density, and multiplied it by the volume of the outer two-third of the DG molecular layer to get the total synapse number. For the stereological measurement of the number of granule cells, another systematic random series of 50-μm-thick sections—250 μm apart from each other—were collected from the entire hippocampi of 12 animals. Sections were washed in PB, treated with 0.3% saponin in PB, incubated in Mayer’s Hematoxylin solution (DAKO, Glostrup, Denmark; diluted 1:20 in PB) for 30 min, washed in running tap water for 10 min, rinsed in distilled water, washed in PB and mounted and coverslipped with Aqua-Poly/Mount (Polysciences, Hirschberg an der Bergrasse, Germany). Stereology was performed on a Zeiss Axioskop 2 mot plus microscope, using a Plan-Apochromat × 100/1.4 oil immersion objective, Q-Imaging CCD camera and Stereo Investigator software (MBF Bioscience). The optical fractionator method was used as described earlier. Section thickness was checked in every counting frame (7 × 7 μm, height: 25 μm); x–y step size was 100 μm. At least 7-μm-thick volume at the top and bottom of every section was kept as guard zones.

Analysis

WT and G27Tg animals were selected randomly, after we identified litters, in which sufficient numbers of both WT and G27Tg mice were present. Sample sizes were estimated based on pilot investigations. In all five experiments, described in the five Results sections, investigators were blinded to the group allocations during the experiment and while assessing the outcomes. Data populations with Gaussian distributions (tested with Shapiro–Wilks W-test) were compared with parametric tests and other distributions were compared with non-parametric tests. The Mann–Whitney W-test was used for the analysis of synaptic cleft width and PSD thickness. Spearman R correlation was used for the analysis of the synaptic GluN1 content. Two sample t-test was used to compare total synapse number of different groups, and Friedman test was used for the analysis of granule cell numbers. The null hypothesis was
RESULTS

G72Tg animals have larger glutamatergic synapses in DG and it is restored by NAC treatment

The synaptic active zone area of randomly sampled synapses was measured in the outer two-thirds of the DG molecular layer because this area is the termination zone of the perforant path, and 85% of all asymmetric synapses here originate from these fibers. Synapses were 3D-reconstructed from serial electron microscopic sections (about two to five section per synapse; Figure 1a), and synaptic areas were calculated accordingly (see Materials and Methods).

First, we measured synaptic areas of five WT and G72Tg littermate pairs, and found a significant increase of synaptic area in G72Tg animals in all five investigated littermate pairs (L#1: WT: n = 32, 3D-reconstructed synapses, median = 25.97 × 10³ nm², G72Tg: n = 24 synapses, median = 34.46 × 10³ nm², P = 0.013; L#2: WT (n = 52, 24.25 × 10³ nm²), G72Tg (n = 38, 30.89 × 10³ nm²), P = 0.024; L#3: WT (n = 43, 20.96 × 10³ nm²), G72Tg (n = 28, 29.51 × 10³ nm²), P = 0.014; L#4: WT (n = 24, 18.77 × 10³ nm²), G72Tg (n = 14, 29.95 × 10³ nm²), P = 0.029; L#5: WT (n = 30, 21.26 × 10³ nm²), G72Tg (n = 59, 28.09 × 10³ nm²), P = 0.003). In the pairwise comparisons of littermates, the median increase was 33%, min–max: 27–60% (Figure 1b). The ages of the littermates (see Materials and Methods) did not correlate either with synaptic area or with the extent of the observed changes (data not shown).

In the second set of experiments, we examined the effect of NAC treatment on changes in synaptic areas (Figure 1c). We used three groups of littermates, each consisting of a WT, a G72Tg and a NAC-treated G72Tg (G72TgN) animal. We found again that synaptic areas were significantly increased in G72Tg animals, and values in each of these littermate groups significantly decreased back to the normal level in NAC-treated G72TgN mice (L#6: WT (n = 62, 23.61 × 10³ nm²), G72Tg (n = 48, 28.83 × 10³ nm²), G72TgN (n = 87, 20.36 × 10³ nm²), WT versus G72Tg P = 0.042, G72Tg versus G72TgN P < 0.001; L#7: WT (n = 69, 20.79 × 10³ nm²), G72Tg (n = 49, 35.33 × 10³ nm²), G72TgN (n = 51, 27.68 × 10³ nm²), WT versus G72Tg P < 0.001, G72Tg versus G72TgN P = 0.004; L#8: WT (n = 60, 20.53 × 10³ nm²), G72Tg (n = 56, 25.40 × 10³ nm²), G72TgN (n = 78, 22.14 × 10³ nm²), WT versus G72Tg P = 0.046, G72Tg versus G72TgN P = 0.031; Figure 1c).

Because synaptic areas of different mice in the same groups (WT, G72Tg or G72TgN) did not differ significantly, we pooled synaptic areas within these groups. The median synaptic area was 22.15 (interquartile range: 16.48–30.90) × 10³ nm² (n = 386) in WT mice, 29.74 (21.74–43.00) × 10³ nm² (n = 316) in G72Tg mice and 21.89 (16.75–28.98) × 10³ nm² (n = 216) in G72TgN mice. This means that the synaptic area increased by 33% in G72Tg animals, compared with WT mice (P < 0.001), and decreased by 35% (of WT

![Figure 1](image_url)

**Figure 1.** G72Tg mice have larger synapses, the sizes of which are normalized by N-acetylcysteine (NAC) treatment. (a) Electron micrographs show representative glutamatergic excitatory synapses sampled from the outer two-thirds of the dentate gyrus molecular layer from wild-type (WT, a’), G72 transgenic (G72Tg, a”) and NAC-treated G72 transgenic (G72TgN, a”’) animals (synaptic active zone edges are indicated with arrows). Scale bar: 200 nm for all images. (b, c) Dots represent the median values of 3D-reconstructed synaptic areas in individual animals, and whiskers mark 40–60 percentile boundaries. Effects were tested in five littermate pairs (b, their values are connected) and in three littermate pairs (c), and then the G72 effect was reversed by the NAC treatment in G72TgN littermates (c, *P < 0.05). Numbers indicate litters. Litter number 1 (L#1): WT: n = 32 3D-reconstructed synapses, G72Tg: n = 24, P = 0.013; L#2: (n = 52, 38), P = 0.024; L#3: (n = 43, 28), P = 0.014; L#4: (n = 24, 14), P = 0.029; L#5: (n = 30, 59), P = 0.003; L#6: WT (n = 62), G72Tg (n = 48), G72TgN (n = 87), WT versus G72Tg P = 0.042, G72Tg versus G72TgN P < 0.001; L#7: (n = 69, 49, 51), WT versus G72Tg P < 0.001, G72Tg versus G72TgN P = 0.004; L#8: (n = 60, 56, 78), WT versus G72Tg P = 0.046, G72Tg versus G72TgN P = 0.031.
values) in NAC-treated G72TgN mice compared with G72Tg animals (P < 0.001). These results show that the G72 gene strongly affects synapses, and the NAC treatment can completely reverse these effects.

Larger synapses contain more NMDA receptors in G72Tg animals as well

NMDARs have heterotetrameric structure with two obligatory GluN1 subunits. Because NMDAR content correlates with synaptic area, larger synapses contain more NMDARs. To confirm that such a correlation exists here as well, we carried out quantitative post-embedding immunogold experiments, using a GluN1 subunit-specific antibody. Synaptic area increase in G72Tg animals and the effect of the NAC treatment on synaptic areas could also be observed in these experiments (Figure 2a). We found that synaptic areas and their NMDAR content showed significant correlations (Figure 2b) in WT (P < 0.001, Spearman R = 0.404, n = 94 3D-reconstructed synapses), G72Tg (P = 0.438, R = 0.346, n = 118) and G72TgN animals (P < 0.001, R = 0.346, n = 129) and also when these data were pooled (P < 0.001, R = 0.385). According to the latter correlation, 33% increase in synaptic area (described above) corresponds to a ~22% increase in synaptic NMDAR content in G72Tg mice.

Synaptic cleft width and PSD thickness are unchanged in G72Tg animals

Certain types of synaptic plasticity can influence synaptic scaffolding and synaptic adhesion molecules and can, therefore, influence cleft width and the thickness of PSD. We compared these features between WT and G72Tg animals. Asymmetric synapses were sampled from the outer two-thirds of the DG molecular layer, and examined in the electron microscopic images (Figures 3a and b). The width of the synaptic cleft and the thickness of PSDs were determined by an unbiased algorithm, using the grayscale levels (Figure 3c). We found that neither cleft width (P = 0.996) nor PSD thickness (P = 0.711) have changed in the G72Tg mice (Figure 3d). The median synaptic cleft width was 18.0 nm (interquartile range: 16.2–19.8) and PSD thickness was 100.08 nm (88.96–122.32) in WT mice (n = 44 synapses from two mice). The median synaptic cleft was 18.0 nm (14.4–21.6) and PSD thickness was 97.30 nm (87.57–123.71) in the G72Tg mice (n = 36 synapses from two mice).

G72Tg animals have fewer synapses in DG and it is restored by NAC treatment

We tested whether the expression of the G72 gene affects the number of synapses. Using quantitative stereological measurements with physical disector method, we estimated the number of synapses in the perisomatic path recipient outer two-thirds of the DG molecular layer (Figures 4a and b) in three triplets of littermates (L#6–8), by taking 18 volume samples per groups (WT, G72Tg, G72TgN). Compared with WT mice (mean = 41.98 × 10⁶, s.d. = ± 7.77 × 10⁶, a total of n = 444 synapses counted), synapse number decreased in G72Tg mice (mean = 32.38 × 10⁶, s.d. = ± 1.07 × 10⁶, n = 36), and G72TgN mice (P = 0.004) and restored near to the normal level after NAC treatment (mean = 41.04 × 10⁶, s.d. = ± 1.08 × 10⁶, n = 417, G72Tg and G72TgN P = 0.021, Figure 4c).

G72Tg animals have fewer granule cells in DG and it is restored by NAC treatment

Using quantitative stereological measurements with optical fractionator method (Figures 4d and e), we tested whether the expression of the G72 gene affects the number of granule cells in DG. Estimations are given for one brain hemisphere in four groups of littermates. Compared with WT mice, the number of cells decreased in all G72Tg mice (with a median of 9%) and restored near to the normal level after NAC treatment (with a median of

Figure 2. Correlation between synaptic N-methyl-d-aspartate (NMDA) receptor content and synaptic area is unaffected by genotype and N-acetylcysteine (NAC) treatment. (a) Electron micrographs show representative glutamatergic synapses sampled from the outer two-thirds of the dentate gyrus molecular layer from wild-type (WT, a’), G72 transgenic (G72Tg, a”) and NAC-treated G72 transgenic (G72TgN, a”’) animals (synaptic active zone edges are indicated with white bars). Post-embedding immunogold labeling against GluN1 NMDA receptor subunit (arrows). Scale bar: 150 nm for all images. (b) Scatterplots show significant (P < 0.01) correlations between synaptic immunogold particle number and synaptic active zone area in WT (Spearman R = 0.404, n = 94 3D-reconstructed synapses), G72Tg (R = 0.438, n = 118), G72TgN (R = 0.346, n = 129) mice, as well as when data were pooled (R = 0.385, n = 341). Animals used for these measurements were taken from litters L#3, L#4, L#6, L#7 and L#8.
7%). The values were 62.13 (WT, n = 380 sample of cells), 56.96 (G72Tg, n = 349) and 60.03 (G72TgN, n = 374) × 10⁴ cells in the first group (L#6); 68.98 (WT, n = 369), 62.22 (G72Tg, n = 335) and 68.13 (G72TgN, n = 370) × 10⁴ cells in the second group (L#7); 79.55 (WT, n = 392), 61.87 (G72Tg, n = 344) and 66.44 (G72TgN, n = 352) × 10⁴ cells in the third group (L#8); and 57.98 (WT, n = 297), 56.56 (G72Tg, n = 324) and 61.39 (G72TgN, n = 348) × 10⁴ cells in the fourth group (L#9) of littermates (Figure 4f). These changes among littermates are statistically significant (P = 0.039).

DISCUSSION

Here we demonstrated that G72 gene expression in a humanized schizophrenia model mouse induces synaptic and cellular changes, and found that these changes are normalized by NAC treatment. Our major findings are that (1) in G72Tg mice, glutamatergic synapses are significantly larger in the main input zone of DG compared with WT littermates and (2) these larger synapses contain more NMDA receptors, whereas receptor density remains unchanged. On the other hand, (3) the number of excitatory synapses targeting DG granule cell spines is decreased in G72Tg animals and (4) there are fewer granule cells in DG. (5) Most importantly, treatment with NAC was efficient in normalizing all these alterations, suggesting that oxidative stress has a major role in G72 gene-induced pathology.

G72 gene polymorphisms confer susceptibility to schizophrenia¹³ and bipolar disorder.²⁹,³⁰,⁴⁵ Schizophrenic patients with G72 gene polymorphisms have an elevated level of LG72 protein in the brain and plasma.¹⁵,¹⁶ G72Tg mice express G72 transcripts similar to those in humans, including the longest open reading frame, LG72.²² Expression of G72 transcripts was highest in DG,²² a brain area frequently affected in schizophrenia and bipolar disorder (see Introduction). G72Tg mice show schizophrenia-like behavioral alterations, including a massive DG-dependent deficit in spatial learning ability.²³ These hippocampal circuits, responsible for learning and memory, are mainly glutamatergic. The ‘glutamate hypothesis’ of schizophrenia suggests a dysregulation of the glutamatergic system with a hypofunction of NMDA-type ionotropic glutamate receptors, along with changes in the number of NMDARs in specific brain regions.⁴,⁵ In schizophrenia, many glutamate-regulated processes seem to be perturbed, which lead to a decreased number of excitatory synapses resulting in insufficient neuronal circuits.² This is exactly what we found in G72Tg mice. Similar changes may occur in patients with G72 gene polymorphisms with consequently higher LG72 protein levels.

Unlikely effect of G72 on DAO in DG

Previously, LG72 was considered to be a modulator of the D-serine-degrading enzyme, DAO.¹⁴,¹⁸,¹⁹ D-serine and glycine are NMDAR co-agonists that have a common binding site on NMDARs. In the hippocampal formation, D-serine seems to be the main co-agonist of NMDARs because its density is high in the hippocampus and the outer two-thirds of the DG molecular layer, whereas glycine is absent in these regions.⁴⁶,⁴⁷ D-serine is essential for the physiological function of the adult DG and it is also necessary for full NMDAR function.⁴⁸ A reduction in D-serine levels can be observed in patients with schizophrenia¹⁹,⁵⁰ and treatment with this amino acid results in ameliorated symptomatology.⁵¹,⁵² However, only low levels of DAO are present in the molecular...
LG72 can in the mitochondrial enzyme methionine-R-sulfoxide reductase B2 complex I function results in increased generation of reactive proteins also suggest a connection between LG72 and complex I.

LG72 has been shown to be located in mitochondria. Recently, Possible role of G72 in the regulation of oxidative stress. The number of synapses and granule cells decreased in G72Tg mice, and it was normalized by N-acetylcysteine (NAC) treatment. (a) Light micrograph shows a hippocampal section before measurements. White dashed line marks the molecular and granule cell layer border of the dentate gyrus, stripes indicate the outer two-thirds of the molecular layer, from where the samples were collected. (b) Electron micrograph shows an image from a series used for physical disector method. Green/red lines show the stereological counting frame (5 × 5 μm). (c) The number of synapses in the outer two-thirds of the molecular layer is decreased in G72Tg mice. This effect is reversed by NAC treatment in G72TgN mice. Dots represent individual measurements (n = 18 in each group), lines represent the mean values (WT: 41.98 × 10^8, s.d. = ±7.77 × 10^7; G72Tg: 32.38 × 10^8, s.d. = ±1.07 × 10^8; G72TgN: 41.04 × 10^8, s.d. = ±1.08 × 10^8). WT versus G72Tg P = 0.004, G72Tg versus G72TgN P = 0.021. Total number of synapses counted during stereological measurements: WT: 444 synapses, G72Tg: 327 synapses, G72TgN: 417 synapses. (d) Light micrograph shows the dentate gyrus. White dashed line marks the granule cell layer (the sampling area). (e) Light micrograph from optical fractionator measurement. Green/red lines: stereological counting frame (7 × 7 μm). Hematoxylin-labeled nuclei of granule cells (purple) were counted. (f) Number of granule cells is decreased in G72Tg mice, which is reversed by NAC treatment (*, Friedman test P < 0.05). Note that the optical fractionator method used in this experiment results in a single final value for every individual animal investigated (dots). Values connected by lines correspond to littermates. Numbers indicate litters. Litter number 6 (L#6): WT: number of granule cells (G72TgN: number of granule cells) were counted. (g) Western blot showing expression levels of GSH-related proteins. GSH enzyme activities were measured in G72TgN mice. (h) Western blot showing expression levels of GSH-related proteins. GSH enzyme activities were measured in G72TgN mice. (i) Western blot showing expression levels of GSH-related proteins. GSH enzyme activities were measured in G72TgN mice. (j) Western blot showing expression levels of GSH-related proteins. GSH enzyme activities were measured in G72TgN mice. (k) Western blot showing expression levels of GSH-related proteins. GSH enzyme activities were measured in G72TgN mice.

Possible role of G72 in the regulation of oxidative stress. LG72 has been shown to be located in mitochondria. The mitochondrial enzyme methionine-R-sulfoxide reductase B2 has been identified as a binding partner of LG72, suggesting that LG72 can influence oxidative stress regulation. Subcellular localization and the ability of LG72 to bind flavin-containing proteins also suggest a connection between LG72 and complex I of the mitochondrial respiratory chain.

Complex I is often affected in schizophrenia and bipolar disorder. Impaired complex I function results in increased generation of reactive oxygen species. Because complex I is highly susceptible to oxidative damage, this leads to a vicious circle and results in the depletion of antioxidants. Consequent oxidative stress has a role in the generation of both schizophrenia and bipolar disorder.

This is represented as a reduction in the GSH level in patients suffering from these diseases. G72 transgenic mice show signs of altered mitochondrial function and oxidative stress. Furthermore, these mice also possess decreased complex I activity and a reduction in the GSH level. The effectiveness of the putative GSH precursor NAC in ameliorating cognitive, cellular and subcellular alterations of G72Tg mice (present study) confirms the possible role of G72 transcripts in the regulation of oxidative stress.

NMDARs have a redox-sensitive modulatory site. Oxidative environment can inhibit NMDAR function up to 50%. Depleted GSH level does also have a direct effect on NMDARs, whereas the GSH level is decreased in G72Tg mice, similar to patients suffering from schizophrenia or bipolar disorder. Although we did not assess NMDAR hypofunction here directly, the potential link between NMDAR hypofunction and oxidative stress in the pathogenesis of schizophrenia has also been proposed before. Here, we hypothesize that larger synapses with more NMDARs observed in the molecular layer of G72Tg mice are a response to NMDAR hypofunction due to oxidative damage. These larger synapses are necessary and sufficient to maintain basal synaptic activity; however, they are unable to adapt to further potentiation demands, resulting in decreased plasticity and cognitive deficits of these mice. In addition, although changes in the synaptic structural profile often accompany physiological alterations of neurons, we found no difference in synaptic cleft width or PSD thickness of G72Tg mice compared with WT animals, further suggesting an intact synaptic architecture, but changed NMDAR-related functions.

Furthermore, damaged presynaptic mitochondrial activity may also have a role in the observed changes. Electrophysiological investigations of these synapses revealed unchanged basal activity, but a deficit in sustaining high-frequency transmission and in paired-pulse facilitation, suggesting a presynaptic impairment and damaged mitochondrial function. This may also
result in a postsynaptic compensatory change that helps to maintain a certain level of synaptic activity by increasing synaptic size and receptor content.

We found a decrease in the number of granule cells (~9%) and an even larger decrease in their synapses (~23%) decrease), which suggests that the decline in the number of granule cells does not account for all the losses of excitatory synapses on their dendrites. This means that, on average, each individual granule cell receives less glutamatergic input in G72Tg animals compared with WT mice. The observed changes may be either because of an NMDAR hypofunction or are directly induced by oxidative stress in the DG. Granule cells are continuously generated in DG, even in adulthood, and newborn cells are indispensable for circuit formation and essential for intact learning and memory processes. The survival of newborn neurons depends on proper NMDAR function. On the other hand, neurogenesis is highly sensitive to oxidative stress. Furthermore, oxidative environment promotes the aging of cells, shortening their lifetime. Decreased neurogenesis has been linked to schizophrenia, whereas neuronal atrophy is thought to accompany bipolar disorder. These processes can lead to a lower number of dentate granule cells, which we found in G72Tg animals, whereas insufficient synaptic connectivity in the DG may be responsible for impaired spatial learning ability of these mice. Beneficial effects of NAC treatment

NAC is currently used in acetaminophen overdose and as a mucolytic agent. It provides protection against oxidative stress, can enhance cystine-glutamate antiporter, reduce inflammatory cytokines and has been trialed in several psychiatric disorders. NAC was effective in bipolar disorder, and also in ameliorating negative symptoms in patients with schizophrenia. In G72Tg animals, the reduced GSH level could be rescued by treatment with NAC.

In the present study, we have shown that oral NAC treatment can effectively normalize cellular and synaptic alterations of G72Tg mice, and we present the first high-resolution anatomical evidence that NAC can directly act at cellular and synaptic levels. If the presence of G72-susceptibility polymorphisms could be routinely detected by responsible genetic profiling in schizophrenia or bipolar disorder patients, NAC treatment could provide a personalized causal treatment for deficits caused by G72 polymorphisms, and these human patients may see an improvement in negative and cognitive deficits—a field where most current antipsychotics fail. These beneficial effects could be achieved with the repurposing of a cheap, simple and safe drug, which is already used in other fields of medicine.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

The technical assistance of Katalin Lengyel, Emőke Simon, Katalin Iványi and Győző Goda is greatly appreciated. This work was supported by the National Institutes of Health (grant number NS030549). GN was supported by a János Bolyai Research Scholarship, Hungary.

REFERENCES

1 Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738–1749.
2 Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 2003; 97: 153–179.
3 Drews E, Otte DM, Zimmer A. Involvement of the primate specific gene G72 in schizophrenia: from genetic studies to pathomechanisms. Neurosci Biobehav Rev 2013; 37: 2410–2417.

4 Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 2003; 1003: 318–327.
5 Kantrowitz JT, Javitt DC. N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 2010; 83: 108–121.
6 Javitt DC, Zukin SR. Recent advances in the phenylcyclohexane model of schizophrenia. Am J Psychiatry 1991; 148: 1301–1308.
7 Krystal JH, Karper LP, Seibel JP, Freeman GK, Delaney R, Brenner JD et al. Sub-anesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199–214.
8 Parwani A, Weiler Ma, Blaxton Ta, Warfel D, Hardin M, Frey K et al. The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berl) 2005; 183: 265–274.
9 Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234–242.
10 Wotkin a, Sanfilippo M, Angrist B, Duncan E, Wieland S, Wolf A et al. Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology. Biol Psychiatry 1994; 36: 317–325.
11 Murphy BP, Chung Y-C, Park T-W, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88: 5–25.
12 Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuro-pathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40–68, image 5.
13 Labrie V, Wong AHC, Roder JC. Contributions of the d-serine pathway to schizophrenia. Neuropharmacology 2012; 62: 1484–1503.
14 Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palacio M, Abderrahim H et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 2002; 99: 13675–13680.
15 Korostishevsky M, Kaganovich M, Ashkenazi M, Ratner Y, Dahary D et al. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 2004; 56: 169–176.
16 Lin C-H, Chang H-T, Chen Y-J, Huang C-H, Tun R, Tsai GE et al. Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. Mol Psychiatry 2014; 19: 636–637.
17 Papouin T, Ladépêche L, Ruel J, Sacchi S, Labasque M, Hanini M et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012; 150: 633–646.
18 Sacchi S, Bemasconi M, Martineau N, Mothet JP, Ruzzene M, Pilone MS et al. The C-terminal region of G72 modulates intracellular D-serine levels through its interaction with pLG72. J Biol Chem 2008; 283: 22244–22256.
19 Chang SL, Hsieh C, Chen Y, Wang C, Shih C, Huang P et al. The C-terminus region of G72 increases D-amino acid oxidase activity. Int J Mol Sci 2013; 15: 29–43.
20 Otte D-M, Raskó T, Wang M, Dreiseder M, Drews E, Schrage H et al. Identification of the mitochondrial M58B2 as a binding partner of LG72. Cell Mol Neurobiol 2014; 34: 1123–1130.
21 Kvajo M, Dhilla A, Swoer DE, Karayiorgou M, Gogos JA. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial dysfunction. Mol Psychiatry 2008; 13: 685–696.
22 Otte DM, Bilkei-Gorzdi A, Filloiu MD, Turk CW, Yilmaz O, Holost Mi et al. Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol 2009; 19: 339–348.
23 Otte D-M, Sommersberg B, Kudin A, Guerrero C, Albayram O, Filloiu MD et al. N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology 2011; 36: 2233–2243.
24 Kirov I, Hardy CJ, Matsuda K, Messinger J, Cankurtaran CZ, Warren M et al. In vivo 7Tesla imaging of the dentate granule cell layer in schizophrenia. Schizophr Res 2013; 147: 362–367.
25 Hagihara H, Takao K, Walton NM, Matsumoto M, Miyakawa T. Immature dentate gyrus: an endophenotype of neuropsychiatric disorders. Schizophr Res 2013; 150: 303–313.
26 Stan AD, Ghose S, Halsey K, Mihalakos P, Yaniagi M et al. Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia. Mol Psychiatry 2015; 20: 433–439.
27 Das T, Ilevua EI, Wagner AD, Stark CE, Tammenga CA. Loss of pattern separation performance in schizophrenia suggests dentate gyrus dysfunction. Schizophr Res 2014; 159: 193–197.
Evidence for reduced dentate gyrus and fimbria volume in bipolar II disorder. Bipolar Disord 2013; 15: 167–176.

Gatt JM, Burton KLO, Williams LM, Schofield PR. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J Psychiatr Res 2015; 60: 1–13.

Detera-Wadleigh SD, McMahon FJ. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 2006; 60: 106–114.

Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013; 74: 400–409.

Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011; 29: 311–324.

Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011; 15: 2011–2035.

Raffa M, Barhoumi S, Atig F, Fendri C, Kerkeni A, Mechri A. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 2012; 39: 371–375.

Lavoie S, Murray MM, Deppen P, Krzyazeva MG, Berk M, Boulou O et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008; 33: 2187–2199.

Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I et al. N-acetyl-cysteine as a glutathione precursor for schizophrenia-A double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64: 361–368.

Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011; 135: 389–394.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Mallis GS, Kohlmann K et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011; 33: 374–378.

Fukaya M, Kato A, Tonegawa S, Watanabe M. Retention of NMDA receptors at central synapses. J Neurosci 1992; 256: 1217–1221.

Nusser Z. A new approach to estimate the number, density and variability of N-methyl-D-aspartate receptors at central synapses. Glutamate-induced transient modification of the postsynaptic density. Proc Natl Acad Sci USA 2006; 103: 4855–4860.

West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the regional and developmental localizations in rat brain glia resemble NMDA receptor NR2 subunits in the lumen of endoplasmic reticulum in targeted NR1 knockout mice. Proc Natl Acad Sci USA 2003; 100: 1337–1342.

Amaral DG, Scharfman HE, Lavenex P. The dentate gyrus: fundamental anatomical organization (dentate gyrus for dummies). Behav Brain Sci 2007; 123: 3–22.

Bendikov I, Nadri C, Panizzutti R, De Miranda J, Wolosker H et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90: 41–51.

Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antidepressants for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081–1089.

Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G et al. D-serine efficacy as add-on pharmaceutical to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57: 577–585.

Sasabe J, Suzuki M, Imanishi N, Aiso S. Activity of D-amino acid oxidase is widespread in the human central nervous system. Front Synaptic Neurosci 2014; 6: 1–10.

Billiard J. d-Serine in the aging hippocampus. J Pharm Biomed Anal 2015; 116: 18–24.

Rosenfeld M, Brenner-Lavie H, Ari SGB, Kavushansky A, Ben-Shachar D. Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol Psychiatry 2011; 69: 980–988.

Scola G, Kim HK, Young LT, Andreaza AC, A fresh look at complex i in microarray data: Clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol Psychiatry 2013; 73: 64–65.

Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39: 359–407.

Brown NC, Andreaza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 2014; 218: 61–68.

Mühlani FE, Sedak TW, Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry 2014; 27: 185–190.

Salim S. Oxidative stress and psychological disorders. Curr Neuropsychopharmacol 2014; 12: 140–147.

Filou MD, Teplytska L, Otte DM, Zimmer A, Turck CW. Myelination and oxidative stress alterations in the cerebellum of the G72/G30 transgenic schizophrenia mouse model. J Psychiatr Res 2012; 46: 1359–1365.

Gozlan H, Ben-Ari Y. NMDA receptor redox sites: are they targets for selective neuronal protection? Trends Pharmacol Sci 1995; 16: 368–374.

Steullet P, Neijt HC, Cuénot M, Do KQ. Synaptic plasticity impairment and dysfunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia. Neuroscience 2006; 137: 807–819.

Hardingham G, Do KQ. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci 2016; 17: 125–134.

Weeks ACW, Ivancio TL, Leboutillier JC, Racine RJ, Petit TL. Sequential changes in the synaptic structural profile following long-term potentiation in the rat dentate gyrus. II. Induction/early maintenance phase. Synapse 2000; 36: 286–296.

Benson DL, Schnapp LM, Shapiro L, Huntley GW. Making memories stick: cell-adhesion molecules in synaptic plasticity. Trends Cell Biol 2000; 10: 473–482.

Dosemeci a, Tao-Cheng JH, Vinade L, Winters Ca, Pozzo-Miller L, Reece TS. Glutamate-induced transient modification of the postsynaptic density. Proc Natl Acad Sci U S A 2001; 98: 10428–10432.

Song JM, Christian K, Ming GL, Song H. Modification of hippocampal circuitry by adult neurogenesis. Dev Neurobiol 2012; 72: 1032–1043.

Tashiro A, Sandler VM, Tioni N, Zhao C, Gage FH. NMDA-receptor-mediated, cell-specific integration of new neurons in adult dentate gyrus. Nature 2006; 442: 929–933.

Huang TT, Zou Y, Corniola R. Oxidative stress and adult neurogenesis-effects of radiation and superoxide dismutase deficiency. Semin Cell Dev Biol 2012; 23: 738–744.

Sasaki M, Kajiya H, Ozeki S, Okabe K, Ikebe T. Reactive oxygen species promotes cellular senescence in normal human epidermal keratinocytes through epigenetic regulation of p16INK4a. J Invest Dermatol 2001; 117: 622–628.

Reif a, Fritzten S, Finger M, Strobel a, Lauer M, Schmitt a et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514–522.

Lu RB, Chen SL, Lee SY, Chang YH, Chen SH, Chu CH et al. Neuroprotective and neurogenesis agent for treating bipolar II disorder: add-on memantine to mood stabilizer works. Med Hypotheses 2012; 79: 280–283.

Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36: 78–86.